Transthyretin Amyloidosis Treatment Market Analysis & Forecast: 2026-2033
The transthyretin amyloidosis treatment market is anticipated to grow at a CAGR of 7.8% with USD 12.1 Bn in 2026 and is expected to reach USD 20.4 Bn in 2033. The substantial growth is expected to be driven by rising awareness and diagnosis of transthyretin amyloidosis (59.8 cases per million people), growing adoption of disease-modifying therapies, increasing investments in rare disease research, and continued advancements in precision medicine are expected to drive market growth.
Tafamidis (Vyndaqel) is projected to account for the largest share of drug type in 2026, representing approximately 45% of the total volume. Its critical role as the first approved therapy particularly for transthyretin amyloidosis cardiomyopathy (ATTR-CM) is one of the factors propelling the growth of the segment.
ATTR-ACT Showed that Tafamidis majorly Reduced the Combination of All-cause Mortality as well as Cardiovascular-related Hospitalizations Data Showed a 30% Reduction in the Risk of Mortality and 32% Reduction in the Rate of Cardiovascular-related Hospitalizations with Tafamidis in People with Transthyretin Amyloid Cardiomyopathy versus Placebo
Developed by Pfizer, Tafamidis functions as a transthyretin stabilizer that prevents the dissociation of tetrameric transthyretin into monomers, hence reducing the formation of amyloid deposits. The market for drug dominance is its oral administration route, which provide major convenience compared to intravenous alternatives, and its approval across multiple jurisdictions including the United States, European Union, and Japan.
The landmark ATTR-ACT trial, which showed Tafamidis's efficacy in reducing cardiovascular-related hospitalizations and all-cause mortality in patients with ATTR-CM, has been instrumental in establishing its clinical credibility as well as physician confidence.
Based on disease type, Hereditary Transthyretin Amyloidosis dominates the market, accounting for a significant 60% share in 2026, earlier disease recognition, established diagnostic protocols, as well as the availability of targeted therapeutic interventions specifically made for genetic variants of the condition. Cancer has come up as the prominent therapeutic area, accounting for 35% of all new drug approvals, augmented by targeted therapies, with kinase inhibitors showing nearly half of these drugs.
The hereditary form of transthyretin amyloidosis, caused by mutations in the TTR gene, has been majorly studied and documented by organizations including the Amyloidosis Research Consortium, as well as the International Society of Amyloidosis, leading to comprehensive treatment guidelines that have showed high clinical adoption.
The dominance of this segment can be attributed to the fact that over 130 different TTR gene mutations have been identified globally, creating a substantial patient population requiring specialized care.
To learn more about this report, Request Free Sample
Based on distribution channel, hospital pharmacies dominant the market, accounting for a significant 50% share in 2026, the complex nature of TTR amyloidosis diagnosis and treatment protocols that require specialized medical infrastructure and continuous physician oversight is one of the factors propelling the market growth.
Hospital pharmacies serve as the primary distribution channel as TTR amyloidosis usually presents with multi-systemic manifestations affecting the heart, nervous system, other vital organs, etc., necessitating comprehensive inpatient and outpatient care coordination that can only be effectively managed within hospital settings.
The requirement for specialized diagnostic procedures including cardiac magnetic resonance imaging, echocardiography, nerve conduction studies, tissue biopsy confirmation, etc., which are typically available only in hospital environments. CMR scan volumes varied widely across Asia, with high-volume centers reporting from fewer than 100 scans per month to over 20,000 scans per year.
Complementing RNAi technology, antisense oligonucleotide (ASO) therapeutics have released another dimension of genetic medicine. These chemically changed DNA sequences bind to TTR messenger RNA, keeping away protein translation through a different mechanism than RNAi. The technological sophistication lies in the precise chemical modifications that enhance stability, tissue distribution, and cellular uptake while minimizing off-target effects.
The development of generation 2.5 ASOs incorporates advanced chemical modifications including locked nucleic acids and phosphorothioate linkages, significantly improving pharmacokinetic properties and reducing dosing frequency. This technological evolution has enhanced patient compliance and therapeutic effectiveness.
|
Current Event |
Description and its Impact |
|
New FDA and EMA Approvals for RNA-based Therapies |
|
|
Increased Government Funding for Rare Diseases |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
To learn more about this report, Request Free Sample
North America account 55% market share in 2026, its robust healthcare infrastructure, advanced diagnostic capabilities, as well at strong regulatory framework that facilitates rapid adoption of innovative treatments for Transthyretin Amyloidosis (ATTR). The estimated prevalence of overall ATTR amyloidosis was 59.8 cases per million people, that of ATTR-CM was 41.1 cases per million people, and that of ATTR-PN was 15.1 cases per million people.
The United States Food and Drug Administration (FDA) has been at the forefront of approving breakthrough therapies, including Pfizer's Vyndaqel (tafamidis), which held as a major milestone in ATTR treatment.
There are many special centers for amyloidosis treatment around the world. Hospitals like Mayo Clinic, Boston Medical Center, and Stanford University help patients and also do research on this disease. The National Amyloidosis Centre's data indicates that North American healthcare systems have executed overall screening protocols, particularly for cardiac amyloidoselis patients, leading to earlier diagnosis as well as treatment initiation.
The Asia Pacific region is poised to be the fastest-growing region through 2026-2033, expanding at a CAGR of approximately 7.5%. Countries including Japan, China, South Korea, India, etc., have seen a high recognition of amyloidosis cases with the advancements in diagnostic capabilities, including the high adoption of genetic testing as well as imaging modalities that are crucial for early detection of transthyretin amyloidosis. From 1999 to 2023, a total of 52,659 amyloidosis-related deaths were recorded in the US. Most deaths occurred in medical facilities and homes.
For example, Japan, which has a large elderly population vulnerable to wild-type transthyretin amyloidosis, has substantially increased government funding for rare disease research, including amyloidosis, as detailed by the Japanese Ministry of Health, Labour and Welfare’s recent rare disease policy programs.
Moreover, China has experienced a surge in public-private partnerships focused at enhancing rare disease care, with centers of excellence being established in urban hubs like Shanghai and Beijing focusing on amyloidosis management.
First and foremost, the U.S. has one of the most advanced healthcare infrastructures globally, supported by world-class medical research institutions as well as centers of excellence specializing in rare diseases including ATTR.
The presence of prominent institutions including the National Institutes of Health (NIH), and the Amyloidosis Program at major hospitals, including the Mayo Clinic, Cleveland Clinic, etc., plays a pivotal role in early diagnosis, patient management, and clinical trial activities for new therapeutic interventions.
For instance, the U.S. Food and Drug Administration (FDA) has been at the edge of approving novel therapies targeting ATTR, including tafamidis, patisiran, inotersen, etc. This regulatory environment has enabled pharmaceutical companies to focus their research as well as delivery efforts predominantly in the U.S., hence enhancing accessibility to cutting-edge treatments for patients.
Japan contributes the highest share in the Transthyretin Amyloidosis Treatment Market in APAC owing to several critical factors rooted in the country's healthcare infrastructure, advanced research capabilities, and the proactive role of government and non-profit organizations in managing rare diseases like transthyretin amyloidosis.
Japan has long been at the forefront of rare disease diagnosis and treatment due to a well-established system for genetic screening, long-term patient registries, as well as a overall public health insurance coverage that includes innovative and orphan drugs aimed at combating amyloidosis.
The Japanese government sees amyloidosis as a serious health problem. It includes the disease in its rare disease program to help find it early and give proper long-term care to patients.
Furthermore, Japan’s leading pharmaceutical companies, such as Takeda Pharmaceutical Company, have been pivotal in pioneering transthyretin amyloidosis treatment development, particularly with novel therapeutics that focus on the destabilization and clearance of amyloid fibrils.
Some of the major key players in Transthyretin Amyloidosis Treatment market include, Alnylam Pharmaceuticals, Inc., Pfizer, Inc., Prothena Corporation Plc., GlaxoSmithKline Plc., Ionis Pharmaceuticals, Inc., Eidos Therapeutics, and SOM Innovation Biotech, S.L.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 12.1 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 7.8% | 2033 Value Projection: | USD 20.4 Bn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Alnylam Pharmaceuticals, Inc., Pfizer, Inc., Prothena Corporation Plc., GlaxoSmithKline Plc., Ionis Pharmaceuticals, Inc., Eidos Therapeutics, and SOM Innovation Biotech, S.L. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Share
Share
Ghanshyam Shrivastava - With over 20 years of experience in the management consulting and research, Ghanshyam Shrivastava serves as a Principal Consultant, bringing extensive expertise in biologics and biosimilars. His primary expertise lies in areas such as market entry and expansion strategy, competitive intelligence, and strategic transformation across diversified portfolio of various drugs used for different therapeutic category and APIs. He excels at identifying key challenges faced by clients and providing robust solutions to enhance their strategic decision-making capabilities. His comprehensive understanding of the market ensures valuable contributions to research reports and business decisions.
Ghanshyam is a sought-after speaker at industry conferences and contributes to various publications on pharma industry.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
